Janssen Search
Search results
Jennifer L. Taubert
JENNIFER L. TAUBERT EXECUTIVE VICE PRESIDENT WORLDWIDE CHAIRMAN, INNOVATIVE MEDICINE JOHNSON & JOHNSON Jennifer L. Taubert is Executive Vice President and Worldwide Chairman, Innovative Medicine at Johnson & Johnson, the world’s largest healthcare ...
Hepatitis B
Hepatitis B We are committed to easing the burden faced by the many millions of people living with chronic hepatitis B. There are nearly 300 million people chronically infected with hepatitis B today. Fewer than 20% of patients know they have the disease, ...
Our Products
Article Type: Oncology Our Products We have a uniquely broad perspective and the ability to leverage our affiliates’ expertise throughout the cancer journey from prevention, diagnosis and treatment to the return to wellness. As part of the Johnson & ...
Michelle Wang Goodridge
Michelle Wang Goodridge is the Global Commercial Strategy Leader for Infectious Diseases & Vaccines (ID&V). Michelle is responsible for building and maximizing the value of the ID&V pipeline and marketed assets. She joined Johnson & ...
Johnson & Johnson Marks New Era as Global Healthcare Company with Updated Visual Identity
Sep 14, 2023 United States Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide New Brunswick, N.J., Sept. 14, 2023 ...
Focus: Thrombosis
Cardiology & Metabolism Focus: Thrombosis Cardiovascular disease is the leading cause of death worldwide. There is a tremendous need for effective anticoagulants. We currently have novel oral anticoagulant for patients in the United States. We are ...
Amy Han
AMY HAN ONCOLOGY COMMERCIAL DISEASE AREA LEADER SOLID TUMOR TARGETED THERAPIES As Oncology Commercial Disease Area Leader, Solid Tumor Targeted Therapies, Amy is the global oncology strategic leader responsible for the commercial optimization of the solid ...
JCI Initiatives
JCI Initiatives Sep 02, 2020 Subhead: Lorem ipsum dolor sit amet, consectetuer adipiscing elit By combining the agility of a lean team, the resources and industry-leading position of Janssen, and the expertise and reach of innovative collaborators, JCI ...
Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood cancer portfolio and pipeline with new clinical and real-world data at ASH
Nov 29, 2023 United States Data highlights strength of multi-target, multi-platform multiple myeloma portfolio and continued innovation in B-cell malignancies to transform patient outcomes RARITAN, N.J., November 29, 2023 – Johnson & Johnson ...
Science of Immorbidity
2 nd International Symposium, 12 October 2017: The Science of Immorbidity- New Approaches to Prevention in Creating a World Without Disease About the Symposium The word immorbidity describes a state where a person is able to evade the diseases that ...